Abstract P297 – Table 1. Overview of patients harboring resistance after virological failure to a dual therapy based on integrase inhibitors

IDa	Previous ARVs experienced	Time under VS before switch (months)	Baseline cGSS for companion drug	Drugs received at switch	Viremia at GRT (copies/mL)	Time under INI‐based dual therapy (months)	Resistance mutations detected after VF
	No of ARV classes INI	INI						INI MRMs	INI accessory	PI MRM	NRTI MRM	NNRTI MRM
357a	6	RAL	7	F/I	DTG, DRV/r	297560	11.3	Y143YCHR	T97TA	None	None	None
326	5	None	37	F/I	RAL, ATV/r	1786	7.1	G140S, Q148H	None	L90M	M184V	None
1321	5	RAL	1	F/I	RAL, SQV/r	3356	19.5	Y143YCHR	T97A	V32I, L33F, M46I, I47V, I50V, I54L	K70R, K219Q	None
3507	5	RAL	1	F/I	RAL, LPV/r	7590	34.2	N155H	None	M46L, I54V, V82A	M41L, D67G, L210W, T215Y, K219E	None
7583	5	RAL	24	F/I	RAL, NVP	4627	2.1	N155H	None	M46L, I84V	M184V, T215Y	K103N, Y188L
10930	6	None	44	S	RAL, ATV/r	2709	11.6	None	G163R	None	None	None
11067	4	None	16	S	RAL, FPV/r	1045	10.9	Y143S	None	L76V	None	None

Among 12 patients with an available GRT after virological failure, 7 showed resistance. In bold are indicated mutations selected after virological failure. ^athe patient was previously heavily treated and developed the mutation N155H after raltegravir failure. /r = ritonavir‐boosted; ATV = atazanavir; cGSS = cumulative genotypic susceptibility score for companion drugs; DRV = daraunavir; DTG = dolutegravir; F/I = fully/intermediate resistant cGSS; GRT = genotypic resistance test; INI = integrase inhibitor; LPV = lopinavir; MRM = major resistance mutation; NRTI = nucleos(t)ide reverse transcriptase‐inhibitor; NNRTI = non‐NRTI; PI = protease inhibitor; RAL = raltegravir; S = susceptible cGSS; SQV = saquinavir; VF = virological failure; VS = virological suppression.